1. Sotatercept lowered early clinical worsening in pulmonary arterial hypertension.
2. Eleven percent of sotatercept patients worsened vs thirty-seven percent on placebo.
3. Exercise capacity and NT-proBNP levels improved with sotatercept.
4. Epistaxis and telangiectasia occurred more often in the sotatercept group.
5. The trial was stopped early after prior positive results.
6. Funding came from Merck Sharp and Dohme, with academic authors ensuring data accuracy.

Source: The New England Journal of Medicine